SPIA
AMLX icon

Steward Partners Investment Advisory’s Amylyx Pharmaceuticals AMLX Stock Holding History

Steward Partners Investment Advisory’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.9K Sell
1,000
-500
-33% -$7.03K ﹤0.01% 3408
2025
Q4 		$18.1K Hold
1,500
– – ﹤0.01% 3180
2025
Q3 		$20.4K Sell
1,500
-500
-25% -$4.71K ﹤0.01% 3086
2025
Q2 		$12.8K Hold
2,000
– – ﹤0.01% 3103
2025
Q1 		$7.08K Hold
2,000
– – ﹤0.01% 3255
2024
Q4 		$7.56K Hold
2,000
– – ﹤0.01% 3215
2024
Q3 		$6.48K Hold
2,000
– – ﹤0.01% 3109
2024
Q2 		$3.8K Hold
2,000
– – ﹤0.01% 3128
2024
Q1 		$5.68K Hold
2,000
– – ﹤0.01% 3001
2023
Q4 		$29.4K Sell
2,000
-200
-9% -$3.06K ﹤0.01% 2210
2023
Q3 		$40.3K Buy
2,200
+1,100
+100% +$23.3K ﹤0.01% 2006
2023
Q2 		$23.7K Buy
1,100
+100
+10% +$2.7K ﹤0.01% 2205
2023
Q1 		$29.3K Sell
1,000
-100
-9% -$3.47K ﹤0.01% 2087
2022
Q4 		$40.6K Buy
1,100
+50
+5% +$1.77K ﹤0.01% 1926
2022
Q3 		$30K Sell
1,050
-50
-5% -$1.25K ﹤0.01% 2016
2022
Q2 		$21K Hold
1,100
– – ﹤0.01% 2194
2022
Q1 		$14K Buy
+1,100
New +$24.8K ﹤0.01% 2513

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Steward Partners Investment Advisory's AMLX Position: Q1 2026 in Review

Steward Partners Investment Advisory reduced its Amylyx Pharmaceuticals (AMLX) stake by 33% in Q1 2026, selling an estimated $7.03K and leaving 1,000 shares worth $13.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3408.

Steward Partners Investment Advisory first reported a position in AMLX in Q1 2022 and has held it in 17 quarters since. The position peaked at $40.6K in Q4 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Steward Partners Investment Advisory held 1,000 shares of Amylyx Pharmaceuticals worth $13.9K as of Q1 2026.
  • Steward Partners Investment Advisory sold 500 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $7.03K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #3408 holding.
  • Steward Partners Investment Advisory first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • Steward Partners Investment Advisory's Amylyx Pharmaceuticals position peaked at $40.6K in Q4 2022.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.